sorry ma420, I believe you're not reading my post correctly?
paediatric AML is difficult due to rarity and demographic. That's not what management is pursuing
EMD AML, which is our current strategy for 505b2 approval, has a lot of interest from clinicians as it is currently excluded due to difficulty in treatment.
This is what I was trying to relay in my post to Titans.
General Comments / Chat, page-4900
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
0.140(9.93%) |
Mkt cap ! $257.8M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.55 | $1.43 | $419.7K | 282.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13000 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.55 | 31081 | 2 |
View Market Depth
| Last trade - 16.10pm 13/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.52 |
Change
0.140 ( 9.79 %) |
||||
| Open | High | Low | Volume | ||
| $1.45 | $1.55 | $1.44 | 23501 | ||
| Last updated 15.58pm 13/05/2024 ? | |||||
| RAC (ASX) Chart |